Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) Shares Outstanding (Diluted Average) (2019 - 2025)

Celldex Therapeutics has reported Shares Outstanding (Diluted Average) over the past 10 years, most recently at $66.4 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $66.4 million for Q4 2025, up 3.15% from a year ago — trailing twelve months through Dec 2025 was $66.4 million (up 3.15% YoY), and the annual figure for FY2025 was $66.4 million, up 3.15%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $66.4 million at Celldex Therapeutics, up from $66420.0 in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for CLDX hit a ceiling of $66.4 million in Q4 2025 and a floor of $42870.0 in Q4 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $64369.5 (2024), compared with a mean of $15.0 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): crashed 99.89% in 2022 and later surged 103229.21% in 2023.
  • Celldex Therapeutics' Shares Outstanding (Diluted Average) stood at $42870.0 in 2021, then grew by 9.37% to $46888.0 in 2022, then surged by 103229.21% to $48.4 million in 2023, then surged by 32.91% to $64.4 million in 2024, then rose by 3.15% to $66.4 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $66.4 million (Q4 2025), $66420.0 (Q3 2025), and $66388.0 (Q2 2025) per Business Quant data.